Investor Presentaiton

Outlook: 2021 objectives upgraded. 2022 and 2023 objectives excluding Covid unchanged for now eurofins We upgrade 2021 objectives by 13% for revenues and by 36% for EBITDA (all at average H1 2021 exchange rates). FY 2022 and FY 2023 remain unchanged at this time as the duration and magnitude of the COVID-19 related contribution remain impossible to quantify due to uncertainty on new variants and public policy responses. However it is likely that significant levels of testing for COVID-19 may unfortunately continue at a meaningful level at least in 2022. FY 2021 upgraded objectives ○ Revenues o Adjusted EBITDA EUR m 6,150 1,700 FY 2021 previous objectives1 EUR m Revenues 5,450 1,250 FCF-Firm 700 350 Adjusted EBITDA Net Capex SDI (at EBITDA le vel) M&A FY 20222 (Core Business excl. Covid and M&A beyond 31/12/2020) 30 150 о Revenues o Adjusted EBITDA O FCF-Firm 5,450 1,300 750 FY 20232 (Core Business excl. Covid and M&A beyond 31/12/2020) о Revenues o Adjusted EBITDA O FCF-Firm 1 Set on March 1, 2021 5,725 1,375 800 For 2022 & 2023, in addition to these organic objectives, potential proforma revenues from acquisitions of EUR 150m in 2021 and EUR 200m in both 2022 and 2023 (consolidated at mid-year), which would bring Group revenue objectives to: • EUR 5,700m in 2022 9 EUR 6,175m in 2023 2 2022 & 2023 objectives set at average 2020 exchange rates and excluding any revenues from COVID-19 testing and reagents and any M&A beyond 31/12/2020 (i.e. organic Core Business ex. COVID-19 objectives), assuming full return to normal of economies / markets to pre-pandemic levels 86

View entire presentation